Key facts
- Status: Privately Held (no backing).
Leadership
- Daniel RheeChief Technology Officer
- Girish BakhruExecutive Director, Public Equity
- Ji WangExecutive Director, Asia
- Mark JelleyPartner, Credit & Royalty
- ·Watchlist + deal alerts for OrbiMed
- ·The full record, as it builds
Funding rounds
No funding rounds for OrbiMed are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About OrbiMed
Operator of a global investment firm intended to invest in healthcare companies. The company invests in the pharmaceuticals, life sciences, digital health, healthcare technology and biotechnology, medical devices, biopharmaceuticals, and diagnostics sectors.
- Sector
- Financial Services
- HQ
- New York, NY, United States
- Employees
- 160
- Website
- orbimed.com/
- Ownership
- Privately Held (no backing)
OrbiMed doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in OrbiMed shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on OrbiMed in its N-PORT filings yet. We sweep new filings monthly.